Cholinergic and Anticholinergic Drugs

• Acetylcholine synthesis, release, and receptor pharmacology: Acetylcholine is synthesized in nerve terminals by choline acetyltransferase (ChAT) from choline and acetyl-CoA, stored in synaptic vesicles, and released upon action potential-induced calcium influx. ACh then binds to postsynaptic muscarinic G-protein coupled receptors (M1-M5 subtypes) or nicotinic ligand-gated ion channels. Muscarinic receptors couple through Gα proteins to activate (M1, M3, M5 via Gαq/11 → phospholipase C → IP3/DAG signaling) or inhibit (M2, M4 via Gαi/o → adenylyl cyclase inhibition) intracellular cascades. This fundamental distinction explains why anticholinergic effects depend on receptor subtype: M3 blockade causes mydriasis and accommodative paralysis through ciliary muscle relaxation, while M1 blockade impairs cognition through reduced hippocampal acetylcholine signaling. Nicotinic receptors, conversely, are ionotropic channels permeable to sodium and potassium, mediating rapid neuromuscular transmission and ganglionic autonomic effects; cholinergic drugs affecting nicotinic receptors produce fasciculations and paralysis through sustained depolarization (depolarizing agents like succinylcholine) or competitive blockade (non-depolarizing agents).

• Acetylcholinesterase inhibition and cholinergic toxicity: Acetylcholinesterase (AChE) rapidly hydrolyzes ACh in the synaptic cleft (half-life <1 millisecond), terminating cholinergic signaling. Cholinergic agonists increase synaptic ACh concentration either directly (muscarinic/nicotinic agonists like pilocarpine, methacholine) or indirectly by inhibiting AChE (physostigmine, neostigmine, donepezil). AChE inhibitors prevent ACh hydrolysis, causing pathological ACh accumulation at nicotinic and muscarinic sites. This explains the characteristic cholinergic crisis presentation: excessive muscarinic effects produce SLUDGE (Salivation, Lacrimation, Urination, Defecation, GI upset, Emesis) and bronchospasm, while nicotinic overstimulation causes fasciculations, paralysis, and weakness—a critical distinction on exams. Organophosphates and carbamates irreversibly or reversibly inhibit AChE respectively, producing life-threatening cholinergic toxicity manageable only through antimuscarinic therapy (atropine) combined with cholinesterase reactivators (pralidoxime for organophosphates). The molecular basis for atropine's life-saving role in cholinergic crisis lies in its competitive antagonism of muscarinic receptors, effectively blocking pathological ACh at tissue level despite elevated synaptic concentrations.

• Organ-system specific receptor distribution and anticholinergic effects: Muscarinic receptor subtypes show differential tissue distribution determining anticholinergic drug effects: M1 receptors predominate in cerebral cortex and autonomic ganglia (cognition, memory); M2 receptors mediate cardiac sinoatrial and atrioventricular nodal effects (bradycardia, reduced contractility); M3 receptors localize to smooth muscle (bronchial and vascular), exocrine glands (salivary, sweat, GI, urinary), and ciliary muscle (accommodation). Therefore, non-selective anticholinergics like atropine cause mydriasis, cycloplegia, tachycardia, decreased GI motility, urinary retention, and inhibition of sweating—manifestations of M3 blockade predominating peripherally alongside central anticholinergic effects (confusion, delirium, fever). Selective M3 antagonists (tiotropium, ipratropium) exploit muscarinic receptor selectivity to target airway smooth muscle in asthma/COPD while minimizing cardiac and cognitive side effects. This pathophysiological understanding explains why anticholinergic toxicity presents as "hot as a hare, dry as a bone, red as a beet, mad as a hatter"—classical board language denoting hyperthermia, anhidrosis, flushing, and central nervous system dysfunction. Conversely, nicotinic antagonism at the neuromuscular junction (non-depolarizing agents: rocuronium, cisatracurium) produces skeletal muscle paralysis through competitive blockade, exploited perioperatively for surgical relaxation without the dangerous fasciculations of depolarizing agents.

• G-protein signaling cascade specificity: M1, M3, and M5 muscarinic receptors coupled to Gαq/11 activate phospholipase C, generating inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers calcium release from sarcoplasmic reticulum in smooth muscle and exocrine glands, producing bronchial constriction, increased secretions, and GI dysmotility—the muscarinic-mediated effects that anticholinergics effectively block. M2 and M4 receptors coupled to Gαi/o inhibit adenylyl cyclase, decreasing cyclic AMP (cAMP) and producing negative inotropic and chronotropic cardiac effects. This explains why anticholinergics paradoxically increase heart rate: blocking M2-mediated inhibition of adenylyl cyclase removes the "brake" on sympathetic signaling, allowing unopposed β-adrenergic effects. Cholinergic agonists enhance these cascades, and their therapeutic applications in glaucoma (pilocarpine), myasthenia gravis (neostigmine), and Alzheimer's disease (donepezil) leverage M3-mediated miosis, skeletal muscle strengthening, and cognitive enhancement respectively.

• Myasthenia gravis and antibody-mediated neuromuscular dysfunction: Myasthenia gravis results from autoimmune destruction of nicotinic acetylcholine receptors at the neuromuscular junction, reducing the acetylcholine binding sites available for muscle activation. Patients demonstrate profound clinical benefit from cholinergic agonists (neostigmine, pyridostigmine), which increase synaptic acetylcholine concentration through reversible AChE inhibition, saturating remaining functional receptors and improving muscle strength. This mechanism makes acetylcholinesterase inhibitors first-line symptomatic therapy in myasthenia, bridging toward immunosuppressive definitive treatment. The clinical context distinguishes myasthenic crisis (respiratory failure requiring intubation, treated with IV immunoglobulin, plasmapheresis, and cholinergic agents) from cholinergic crisis (excessive AChE inhibitor dosing causing overstimulation, managed by withholding cholinergics and administering atropine).

• Glaucoma and elevated intraocular pressure: Open-angle and closed-angle glaucomas demonstrate elevated intraocular pressure through impaired aqueous humor outflow and/or increased production. Muscarinic agonists (pilocarpine, carbachol) contract the ciliary muscle, increasing trabecular meshwork tension and enhancing aqueous humor drainage through the conventional outflow pathway. Pilocarpine remains a therapeutic option in acute angle-closure glaucoma where its miotic effects pull the peripheral iris away from the trabecular meshwork, reopening the drainage angle. AChE inhibitors (echothiophate) similarly increase intraocular drainage and find use in accommodative esotropia through ciliary muscle contraction. This therapeutic principle represents a classic board vignette: acute angle-closure glaucoma presenting with severe eye pain, redness, and halos around lights, managed acutely with topical pilocarpine, IV acetazolamide, and IV mannitol before definitive laser iridotomy.

• Organophosphate and carbamate poisoning: Agricultural workers, military personnel, and suicide attempt victims encounter organophosphate pesticides (parathion, malathion) and carbamate pesticides (aldicarb, carbaryl) that irreversibly phosphorylate the serine residue at AChE's active site, rendering the enzyme permanently inactive (organophosphates) or temporarily inhibited (carbamates). This produces life-threatening cholinergic overstimulation responsive only to antimuscarinic therapy (atropine in high doses) combined with nicotinic receptor agonism via pralidoxime, a cholinesterase reactivator that cleaves the phosphorus-enzyme bond if administered within hours. This toxidrome scenario represents a high-yield board concept: recognition of cholinergic crisis (SLUDGE + fasciculations + paralysis) in an agricultural or military exposure context, with immediate management including atropine (to block muscarinic effects), pralidoxime (to restore enzyme function), and supportive ventilation.

• Anticholinergic toxicity from medication overdose or atropine poisoning: Excessive anticholinergic drug exposure (anticholinergic medications, antihistamines, antipsychotics with anticholinergic properties, tricyclic antidepressants, or intentional atropine poisoning) causes central and peripheral anticholinergic toxidrome. Risk factors include polypharmacy, renal impairment (reduced drug clearance), advanced age, and genetic polymorphisms affecting metabolism. Children and elderly patients demonstrate particular vulnerability, explaining why anticholinergic medications are contraindicated in these populations. The clinical presentation evolves predictably from sympathomimetic phase (tachycardia, hypertension, agitation) to anticholinergic phase (hyperthermia, flushed skin, mydriasis, delirium, possible seizures).

• Chronic obstructive pulmonary disease and asthma: Long-acting anticholinergics (tiotropium, aclidinium, umeclidinium) block M3 muscarinic receptors on airway smooth muscle, preventing acetylcholine-mediated bronchoconstriction. These agents represent standard maintenance therapy in moderate-to-severe COPD and add-on therapy in asthma, providing sustained bronchodilation without the systemic side effects of non-selective anticholinergics. Ipratropium provides shorter-acting rescue therapy.

• Urinary incontinence and overactive bladder: Detrusor smooth muscle hyperactivity underlying urge incontinence responds to selective M3 antagonists (oxybutynin, tolterodine, solifenacin), which relax bladder smooth muscle and increase storage capacity. These medications demonstrate particular efficacy in neurogenic bladder following spinal cord injury where uninhibited detrusor contractions cause incontinence.

• Cholinergic excess—SLUDGE and muscarinic effects: Excessive cholinergic stimulation produces the characteristic SLUDGE toxidrome: Salivation (excessive drooling from M3-mediated stimulation of salivary glands), Lacrimation (tearing from lacrimal gland activation), Urination (urinary incontinence from detrusor contraction), Defecation (diarrhea and fecal incontinence from increased GI motility), Gastrointestinal upset (nausea, vomiting, cramping from M3-mediated smooth muscle contraction and increased gastric secretions), and Emesis. Additional muscarinic manifestations include bronchospasm and bronchorrhea (excessive bronchial secretions from M3 stimulation of airway mucus glands), bradycardia and hypotension (M2-mediated cardiac effects), and miosis (pinpoint pupils from unopposed ciliary muscle and iris sphincter contraction). These symptoms reflect the peripheral muscarinic receptor predominance in GI, GU, respiratory, ocular, and cardiovascular tissues.

• Cholinergic excess—nicotinic effects: Sustained acetylcholine overstimulation at nicotinic receptors produces characteristic fasciculations (visible muscle fiber twitching from uncoordinated motor unit activation) followed by paralysis and weakness through desensitization of nicotinic acetylcholine receptors. In organophosphate poisoning, visible fasciculations precede muscle weakness and respiratory failure; succinylcholine, a depolarizing neuromuscular blocker used intraoperatively, produces fasciculations before paralysis sets in, creating anesthetic risk if patients are not anesthetized first. Nicotinic effects also include autonomic ganglia stimulation, producing tachycardia, hypertension, and hyperglycemia that may initially dominate the presentation before muscarinic symptoms predominate.

• Anticholinergic toxidrome—classic presentation: Anticholinergic excess produces the quintessential board mnemonic "hot as a hare, dry as a bone, red as a beet, mad as a hatter, fast as a bullet, blind as a bat"—representing hyperthermia (from abolished sweating and increased heat generation), anhidrosis (dry skin and mucous membranes from M3-mediated reduction in sweat gland activity), flushing (cutaneous vasodilation causing redness), delirium (central anticholinergic effects from M1 receptor blockade in cerebral cortex), tachycardia (unopposed sympathetic effects from blocked M2 cardiac inhibition), and mydriasis with cycloplegia (dilated pupils from blocked iris sphincter contraction and paralyzed accommodation from ciliary muscle relaxation). The patient appears acutely agitated, confused, and combative, with altered mental status progressing to hallucinations, seizures, and coma in severe poisoning. Urinary retention and constipation develop from blocked M3-mediated smooth muscle contraction in urinary bladder and GI tract.

• Anticholinergic effects in therapeutic context: Low-dose anticholinergic medications (tricyclic antidepressants, antihistamines, benztropine for Parkinson's disease) produce mild anticholinergic side effects including dry mouth, constipation, urinary hesitancy, tachycardia, and cognitive slowing. Older adults demonstrate exaggerated sensitivity, with anticholinergic medications independently associated with dementia, delirium, and falls in prospective cohort studies—the "anticholinergic burden" concept now guiding drug selection in geriatric medicine.

• Cholinergic drug therapeutic effects: Muscarinic agonists produce organ-specific effects reflecting M3 receptor distribution: miosis and accommodation (pilocarpine in glaucoma), increased salivation (cholinergic agents in Sjögren's syndrome), muscle strengthening (neostigmine in myasthenia gravis), bradycardia, and enhanced GI motility (useful in postoperative ileus). Cognitive improvement characterizes cholinergic enhancement in Alzheimer's disease (donepezil, rivastigmine, galantamine through AChE inhibition increase hippocampal acetylcholine).

• Clinical diagnosis of cholinergic toxidrome: The diagnosis emerges from characteristic symptom clusters in appropriate clinical context (organophosphate/carbamate exposure, cholinergic medication overdose).

Cholinergic agents (direct agonists and AChE inhibitors)

• Bronchospasm and bronchorrhea: M3-mediated airway smooth muscle contraction and mucus gland stimulation make muscarinic agonists (bethanechol, methacholine) and AChE inhibitors relatively contraindicated in asthma and COPD; methacholine's provocative use in bronchoprovocation testing (ATS/ERS technical standards) is the same effect exploited deliberately.
• Bradycardia, AV block, and syncope: M2 blockade of adenylyl cyclase slows SA/AV nodal conduction. Donepezil and other central AChE inhibitors used in Alzheimer disease can unmask sick sinus syndrome or cause syncopal falls; obtain an ECG and review rate-slowing co-medications before starting.
• Peptic ulcer aggravation, urinary and GI hyperactivity: increased acid and motility; bethanechol is contraindicated in mechanical bladder outlet or bowel obstruction because contraction against a fixed obstruction risks perforation.
• Cholinergic crisis: excess pyridostigmine in myasthenia gravis produces SLUDGE plus fasciculations and weakness; management is withholding the drug, supporting ventilation, and antimuscarinic therapy.
• Succinylcholine: depolarizing blockade causes potassium efflux, so it is avoided in burns, crush injury, denervation/upper motor neuron injury, and prolonged immobility because of lethal hyperkalemia; it also triggers malignant hyperthermia (dantrolene, per MHAUS), causes bradycardia especially in children, and produces prolonged apnea in pseudocholinesterase deficiency.

Anticholinergic agents

• Acute angle-closure glaucoma and urinary retention: mydriasis crowds the drainage angle and detrusor relaxation worsens outlet obstruction; the American Geriatrics Society Beers Criteria list strongly anticholinergic drugs as potentially inappropriate in older adults for delirium, cognitive decline, and falls.
• Hyperthermia: anhidrosis impairs evaporative cooling — a real heat-stroke risk in athletes and in exertional or hot environments.

Antidotes and reversal

• Atropine ± pralidoxime: for organophosphate poisoning, atropine is titrated to drying of bronchial secretions; pralidoxime reactivates AChE only before aging.
• Physostigmine: tertiary amine crossing the blood-brain barrier, reverses central antimuscarinic delirium; avoid in tricyclic overdose (sodium bicarbonate is the treatment there).
• Neostigmine plus glycopyrrolate, or sugammadex, reverses non-depolarizing neuromuscular blockade.

• Atropine endpoint in organophosphate poisoning is pulmonary, not pupillary: titrate until bronchial secretions dry and ventilation improves; large cumulative doses are expected. Persistent miosis or tachycardia is not a reason to stop atropine — this is the single most common distractor.
• ***Aging* is the reason pralidoxime is time-critical**: once the phosphorylated enzyme loses an alkyl group, the AChE bond becomes irreversible and oximes no longer reactivate it. Atropine still works because it acts at the receptor, not the enzyme.
• Cholinergic crisis versus myasthenic crisis: both present with weakness and respiratory failure, but cholinergic crisis adds SLUDGE, miosis, and fasciculations. Regardless of cause, the best next step in a patient with a falling vital capacity or negative inspiratory force is airway protection and intubation — not an edrophonium challenge.
• Quaternary versus tertiary amines determine CNS penetration: neostigmine, glycopyrrolate, and pyridostigmine are charged and stay peripheral; physostigmine, atropine, and scopolamine are tertiary and enter the brain. That is why physostigmine — not neostigmine — reverses antimuscarinic delirium, and why glycopyrrolate is paired with neostigmine to blunt muscarinic effects without causing central confusion.
• Tricyclic overdose is the trap: wide QRS with an anticholinergic toxidrome calls for sodium bicarbonate, not physostigmine.
• Bethanechol resists acetylcholinesterase because of its carbamate group, giving it long action on the detrusor — used for non-obstructive urinary retention, contraindicated when obstruction is mechanical.
• Organ-specific classics: pilocarpine for xerostomia in Sjögren syndrome and for angle-closure glaucoma; hyoscyamine/scopolamine for motion sickness and antimuscarinic; benztropine for drug-induced parkinsonism and acute dystonia; ipratropium/tiotropium as GOLD-endorsed COPD bronchodilators with minimal systemic absorption.
• Antimuscarinics precipitate three predictable emergencies: angle-closure glaucoma, acute urinary retention in BPH, and hyperthermia from anhidrosis — the reason the American Geriatrics Society Beers Criteria flag them in older adults.